Similar Items: A Cost Analysis of Adverse Event Management of Systemic Therapies for Metastatic Colorectal Cancer on Patients with at Least Two Previous Lines of Treatment in Spain
- Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy
- First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs
- Cost-Effectiveness Analysis of Annual vs Biennial Fecal Immunochemical Testing for Colorectal Cancer Screening in Japan: A Microsimulation Analysis
- Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis
- Defending Olmstead: Strategies for Combatting Institutional Bias to Improve Access to Mental Health Services in the Least Restrictive Setting
- Cognitive Behavioral Therapy in Early Intervention for Psychosis: A Cost-Effectiveness Analysis